Related Experiment Videos
[Biochemical modulation with sequential methotrexate (MTX)-5-fluorouracil (5-FU) treatment]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 1, 1987
Summary
Sequential methotrexate (MTX) and 5-fluorouracil (5-FU) chemotherapy showed promise for gastrointestinal cancers. Method B, with higher MTX doses and leucovorin rescue, yielded a 40.5% response rate in gastric cancer patients.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Context:
- Gastrointestinal cancers, including gastric and colorectal, present significant treatment challenges.
- Sequential chemotherapy regimens are explored to optimize treatment efficacy.
Purpose:
- To evaluate the efficacy and safety of sequential methotrexate (MTX) and 5-fluorouracil (5-FU) chemotherapy with varying leucovorin rescue schedules in gastrointestinal cancer patients.
Summary:
- A cooperative study compared three sequential MTX-5-FU treatment methods (A, B, C) in gastric and colorectal cancer patients.
- Method B, involving higher-dose MTX (100 mg/m2) and intensive leucovorin rescue, demonstrated a promising 40.5% response rate in gastric cancer.
- While Method A showed some response in colorectal cancer (28.6%), Method B's response rate was lower (20.0%). Median survival varied across groups.
Impact:
- The findings suggest that Method B, a specific regimen of sequential MTX-5-FU with leucovorin rescue, is a promising approach for gastric cancer treatment.
- Further Phase III studies are warranted to confirm these results and explore biochemical modulation in gastric cancer.